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ABSTRACT 
 Colorectal cancer remains the third most common malignancy and the fourth most 
common cause of cancer mortality worldwide. Dysregulated miRNA levels are 
associated with several types of malignancies and may serve as important biomarkers 
and/or therapeutic targets in colorectal cancer.  We examined the role of miRNA-155 on 
tumorigenesis and associated symptoms using a well-characterized mouse model of 
colorectal cancer. C57BL/6 wild-type mice and miRNA-155-/- mice (n=7-13 group) were 
given a single injection of AOM (10mg/Kg) followed by 3 cycles of DSS (2% in the 
water for 1 week followed by 2 weeks of plain water).  A C57BL/6 wild-type group that 
did not receive AOM/DSS treatment was also included as a comparison (n=5).  Mice 
were monitored twice weekly for body weight changes and symptom severity.  Prior to 
sacrifice, body composition measurements were taken. At sacrifice, colon tissue, spleen, 
and adipose tissue were harvested.  miRNA-155-/- mice had significantly fewer tumors 
than wild-type mice.  In addition, miRNA-155-/- mice exhibited a lower symptom 
severity score and a greater body weight gain than wild-type mice over the course of the 
experiment.  In general, wild-type mice had a reduction in fat mass and percent body fat 
as well as fat pad weights compared to the disease-free controls but miRNA-155 
completely offset this effect.  If these findings can be clinically translated, miRNA-155 
may lead to an effective clinical biomarker and/or therapeutic target in colorectal cancer. 
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CHAPTER 1 
INTRODUCTION 
Colorectal cancer remains a significant global health concern; despite advances in 
screening, surgery and treatment and recent reductions in mortality, it remains the third 
most common malignancy and the fourth most common cause of cancer mortality 
worldwide 6, 7, 14, 18.  In the US alone in 2013, it is estimated that over 142,000 new cases 
of colorectal cancer will be diagnosed and that there will be over 50,000 deaths from the 
disease.  These statistics can be attributed largely to the lack of uptake of effective 
screening modalities (especially colonoscopy) that are available for prevention, detection, 
and diagnosis,23, 24 and the fact that colorectal cancer symptoms are rare in the early 
stages so non-screening-detected cancers tend to present in late stage when treatments are 
ineffective13.  Identifying new targets that may play a role in the development and 
progression of colorectal cancer is of significant public health concern, not only from a 
treatment point of view but also for the development of potential biomarkers that can be 
used for assessment and diagnosis of the disease 15.    
Mammalian miRNAs are noncoding RNA oligonucleotides that have emerged as 
potent regulators of gene expression 20. Consequently, dysregulated miRNA levels are 
associated with several types of malignancies 3, 15, 21.  For example, in a recent report 
miRNA-155 was significantly higher in breast cancer tissue than in corresponding non-
tumor tissue and high miRNA-155 expression was correlated with higher tumor grade, 
advanced tumor stage and lymph node metastasis 4.  And further, the disease-free and   
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overall survival rates of the high miRNA-155 group were significantly lower than those 
of the low microRNA-155 group 4.  Another study reported that expression of miRNA-
155 promoted the proliferation of breast cancer cells in vitro as well as the development 
of tumors in nude mice 8.  While there is accumulating evidence to suggest a role for 
miRNA-155 in the development of breast cancer, there are relatively fewer studies that 
report a link between miRNA-155 and colorectal cancer.  A recent report, however, does 
indicate that miRNA-155 is increased in human colorectal cancer samples indicating that 
it may be involved in the progression and development of colorectal cancer 22 but to date 
there have been no studies done in animals to implicate a causal relationship. 
 The purpose of this study was to examine the role of miRNA-155 on the 
development of colorectal cancer. For this, we used a well-established mouse model of 
colorectal cancer, the azoxymethane (AOM) + dextran sodium sulfate (DSS) chemically-
induced model 12, 16, 17.  This model recapitulates the phases of initiation and progression 
of the tumor that occurs in humans 12, 16, 17 . A miRNA-155 knockout mouse was used to 
examine the role of miRNA-155 on colorectal cancer.  We hypothesized that lack of 
miRNA-155 would lead to a decrease in sickness symptoms along with a reduction in 
tumorigenesis.  In this report, we demonstrate that miRNA-155 plays a necessary role in 
the development of colorectal cancer given our findings of a reduction in tumor number 
in miRNA-155 knockout mice.  This miRNA may serve as an important biomarker 
and/or therapeutic target in colorectal cancer.
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CHAPTER 2 
MATERIALS AND METHODS 
Animals.  C57BL/6 wild-type mice and miRNA-155-/- mice on a C57BL/6 
background were bred in the University of South Carolina’s Center for Colon Cancer 
Research (CCCR) Mouse Core Facility.  miRNA-155-/- offspring were genotyped as null 
homozygotes by RT-PCR for the miRNA-155 gene by taking tail snips at weaning. The 
primer sequences for miRNA-155 were as follows: miRNA-155-/-  5'-GTG CTG CAA 
ACC AGG AAG G-3', miRNA-155+/- 5'- CTG GTT GAA TCA TTG AAG ATG G-3', 
and wild-type 5'- CGG CAA ACG ACT GTC CTG GCC G-3'. Mice were maintained on 
a 12:12h light-dark cycle in a low-stress environment (22oC, 50% humidity and low 
noise) and provided food (AIN-76A) and water ad libitum.  All animal experimentation 
was approved by the University of South Carolina's Institutional Animal Care and Use 
Committee.  
AOM/DSS protocol.  An azoxymethane (AOM) + dextran sodium sulfate (DSS) 
chemically induced model of colorectal cancer was used 12, 16, 17.   C57BL/6 wild-type 
mice and miRNA-155-/- mice (n=7-13 group) began their AOM/DSS treatment at 10 
weeks of age.  Briefly, mice were given a single injection of AOM (10mg/Kg) followed 
by 3 cycles of DSS (2% in the water for 1 week followed by 2 weeks of plain water) as 
previously described 12, 16, 17.  A C57BL/6 wild-type group that did not receive AOM/DSS 
treatment was also included as a comparison (n=5).    
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Body Weight and Food & Fluid Intake.   Mice were weighed twice a week 
throughout the 10 week colorectal cancer protocol. Food and fluid intake were monitored 
once a week.    
Body Composition.  Body composition was assessed at twenty weeks (following 
the 10 week colorectal cancer protocol and prior to sacrifice).  For this procedure, mice 
were placed under brief anesthesia (isoflurane inhalation) and were assessed for lean 
mass, fat mass, and body fat percentage via dual-energy x-ray absorptiometry (DEXA) 
(Lunar PIXImus, Madison, WI) 5.   
Symptom Scoring. Symptoms were scored twice weekly throughout the 10 week 
protocol using a standard scoring system that has previously been used in this model.  
Briefly, scores were based on diarrhea, blood in stools and weight loss (see Table 1).  
Diarrhea symptoms were evaluated based on visualization of the fecal matter.  Blood in 
the stools was determined using a Hemoccult Fecal occult blood test.  In addition, weight 
loss was based on the percent change in weight compared to baseline levels.   Mice were 
given scores of 0, 2 or 4 depending on the severity of the symptoms.   
Tissue Collection.  At 20 weeks of age, mice were sacrificed for tissue collection.  
Epididymal, mesentery, and retroperitoneal fat pads as well as the spleen were removed, 
weighed, and immediately snap-frozen in liquid nitrogen and stored at -80°C or fixed in 
10% formalin.  The large intestine was removed from the distal end of the cecum to the 
anus and mesentery tissue was removed with tweezers.  It was flushed with PBS, opened 
longitudinally, and flattened with a cotton swab.  All large intestines were fixed in 10% 
buffered formalin (Fisher Scientific, Pittsburg, PA) for 24 h. 
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Tumor Characteristics. Formalin-fixed large intestines were rinsed in deionized 
water, briefly stained in 0.1% methylene blue, and counted by the same investigator who 
was blinded to the treatments. Tumors were counted under a dissecting microscope, using 
tweezers to pick through the intestinal villi and identify tumors. Tumors were categorized 
by size (>2 mm, 1–2 mm, and <1 mm).  Colon lengths were measured as an indicator of 
inflammation; a shorter colon length is indicative of greater inflammation.   Similarly, 
colon weight was determined as an increase in colon weight has been associated with 
elevated inflammation. 
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CHAPTER 3 
RESULTS 
Body Weight.  Body weight was monitored twice weekly throughout the 10 week 
AOM/DSS protocol.  Body weight over time is expressed as a percent of baseline (i.e. 
normalized to measured body weight prior to the initiation of the AOM/DSS protocol) 
(Figure 1A).  In general, the disease-free control group gained weight at a greater rate 
than both of the AOM/DSS groups; this was significant at most of the time-points 
measured.  When comparing between the AOM/DSS groups, the miRNA-155-/- mice 
had a greater body weight gain than the wild-type mice at 15.5, 18.5, 19.0 and 19.5 weeks 
(P<0.05).  We also measured body weight at sacrifice (Figure 2A).  As expected, the 
wild-type AOM/DSS mice had a decrease in body weight compared to the disease-free 
control wild-type mice (25.47 g versus 31.30 g) (P<0.05) and miRNA-155-/- offset this 
effect; the miRNA-155-/- mice were very similar in weight at end point to the disease-
free wild-type control mice (Figure 2A). 
Symptom Severity.  Symptoms, including diarrhea, blood in stools and weight 
loss, were scored twice weekly throughout the 10 week AOM/DSS protocol.  In general, 
miRNA-155-/- mice exhibited a lower symptom severity score than wild-type mice over 
the course of the experiment (Figure 1B); this reached statistical significance at 12.5, 
14.5, 15, 15.5, 18, 18.5, 19.5 and 20 weeks of age (P<0.05).    
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Spleen Weight.  Spleens were harvested and weighed at sacrifice.  Spleen weight, 
expressed as a percentage of body weight was increased in the wild-type AOM/DSS mice 
compared to disease-free control mice and this effect was offset in the miRNA-155-/-   
AOM/DSS mice (Figure 2B).  However, these effects did not reach statistical 
significance. 
Body Composition. Prior to sacrifice at 20 weeks of age, mice underwent a 
DEXA scan to determine body composition (body fat percentage, fat mass and lean mass) 
(Figure 3).  This was performed as cachexia has been associated with severity of disease 
in colorectal cancer. As expected, the wild-type AOM/DSS mice had a decrease in fat 
mass compared to the disease-free control mice (4.03 ± 0.3 gm vs. 7.16 ± 0.9 gm) 
(P<0.05) and miRNA-155-/- offset this effect; the miRNA-155-/- mice had a very similar 
fat mass (6.48 gm) to the disease-free control mice (Figure 3A).  Similar effects were 
observed for body fat percentage.  The wild-type AOM/DSS mice had a decrease in body 
fat percentage compared to the disease free controls (17.45 ± 0.8% vs. 24.98 ± 2.3%) 
(P<0.05) and this effect was negated in the miRNA-155-/- mice (22.81 ± 1.9%) (Figure 
3B).  There were no significant group differences detected for lean mass at any of the 
time points (Figure 3C). 
Visceral Fat Weights. At sacrifice, epididymal, mesenteric, and retroperitoneal 
fat pads were collected and weighed.  This was done to monitor the degree of fat loss, 
which has been associated with poor outcome in colorectal cancer. As expected, 
epididymal fat mass was decreased in the wild-type AOM/DSS mice compared to the 
disease-free control group (P<0.05) and this effect was offset in the miRNA-155-/- mice 
(Figure 4A). In fact, there was no difference between the disease-free control mice and 
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the miRNA-155-/- mice that underwent the AOM/DSS protocol. Similar effects were 
found for mesenteric (Figure 4B) and kidney fat (Figure 4C); in both cases, the fat mass 
was reduced in wild-type AOM/DSS mice versus the disease free control mice (P<0.05) 
and deficiency of miRNA-155 completely offset this effect.   
Tumor Characteristics.  At 20 weeks of age, mice were sacrificed and the large 
intestine (colon) was harvested and tumors were counted on formalin-fixed, methylene 
blue-stained sections.  miRNA-155-/- mice had significantly fewer tumors than wild-type 
mice (0.17 versus 2.14) (P<0.05) (Figure 5A).   Tumors were also stratified according to 
size (Figure 5B); we classified tumors as being large (> 2mm in diameter), medium (<2 > 
1 mm in diameter) or small (< 1 mm in diameter).  A significant percentage of the tumors 
found in the wild-type AOM/DSS mice were considered to be large and the only tumors 
present in the miRNA-155-/- mice were medium size (Figure 5B).  After the tumors were 
counted, the colons were then weighed and measured according to length and width 
(mm).  The colon weight (g) was measured as an indication of the amount of 
inflammation present. The wild-type AOM/DSS mice had a significantly (P<0.05) 
heavier colon weight than the disease-free control mice (Figure 5C) but there was no 
effect of genotype; there was no difference between the wild-type AOM/DSS mice and 
the miRNA-155-/- AOM/DSS mice.  Then a colon length: width ratio was calculated as it 
has been documented that the colon length decreases with inflammation.  Both of the 
AOM/DSS groups showed an increase in colon length: width ratio compared to the 
disease free controls (Figure 5D). 
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CHAPTER 4 
DISCUSSION 
Dysregulated miRNA levels are associated with several types of malignancies 
including colorectal cancer 3, 21.   Several recent reports have indicated that miRNA-155 
is correlated with higher tumor grade, advanced tumor state and lymph node metastasis in 
breast cancer. Although there is accumulating evidence to suggest a role for miRNA-155 
in the development of breast cancer, there are relatively fewer studies that report a link 
between miRNA-155 and colorectal cancer.  Therefore, we examined the role of miRNA-
155 on body weight, body composition, symptom severity and tumorigenesis using a well 
characterized chemically-induced mouse model of colorectal cancer 12, 16, 17.  Our data 
indicates that miRNA-155 plays a significant role in tumorigenesis as well as the 
symptoms associated with colorectal cancer; mice deficient for miRNA-155 had a 
significant reduction in the number of tumors in the colon and this was associated with 
decreased sickness symptoms and prevention of loss of body weight and fat mass that can 
accompany the disease.  
 Knockout mice provide a tool to examine the effects of various genes on 
tumorigenesis.  We used miRNA-155 knockout mice to examine the role of this miRNA 
on colorectal cancer using a well-characterized chemically-induced mouse model (i.e. the 
AOM/DSS model) 12, 16, 17.  The miRNA-155-/- mouse is available in a C57BL/6 
background, a strain that shows high incidence and multiplicity of colonic 
adenocarcinoma following AOM/DSS administration.  The AOM/DSS model is a two-
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stage mouse colorectal carcinogenesis model initiated with AOM and promoted by DSS 
that was developed to  obtain a better understanding of the pathogenesis of inflammatory 
bowel-related colorectal cancer.  In this model, mice initiated with a low dose of a 
colonic carcinogen, AOM (10 mg/kg body wt), develop tumors after a relatively short-
term DSS exposure. The subsequent dysplasia and neoplasms show positive staining for 
β-catenin, COX - 2 and inducible nitric oxide synthase.  Our data indicates that mice 
deficient for miRNA-155 have fewer overall tumors than wild-type mice.  In fact, they 
were approximately 90% lower than those of wild-type mice.  When tumors were 
stratified according to size, miRNA-155-/- mice had significantly lower numbers of 
smaller tumors as well as larger tumors and although medium tumor number was also 
lower in miRNA-155-/- mice, this did not reach statistical significance.   While we did 
observe an increase in colon weight and an increase in the colon length: width ratio in the 
AOM/DSS treated mice compared to the disease free control mice, we did not see an 
effect of genotype within the AOM/DSS groups.  This was surprising given that an 
increase in these outcomes is indicative of inflammation and has been associated with 
increased tumor number.  This may be explained by the overall low incidence of tumors 
in these mice; perhaps a greater number of tumors are needed to clearly observe 
differences in inflammatory outcomes between these groups.  Even so, to our knowledge 
this is the first report of a benefit of miRNA-155 deficiency in a controlled experimental 
mouse model of colorectal cancer. 
We also examined symptom severity during the course of the AOM/DSS 
protocol.  Symptoms were recorded twice weekly and included scoring for diarrhea, 
blood in stools and weight loss.  The presence of these symptoms is not unusual in 
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patients with colorectal cancer.  In fact, diarrhea, blood in stools and weight loss are a 
direct result from colorectal cancer.  The existence of tumors as well as the reduction of 
villi in the colon results in a reduced ability to absorb nutrients during digestion, which 
can lead to diarrhea and weight loss.  Also large tumors can cause bleeding during 
digestion; when the fecal matter is passing through the colon it can catch on the larger 
tumors causing the presence of blood in the stool especially if there is an absence of villi 
in the colon.  Greater symptom scores indicate increased severity of the cancer.  In the 
wild-type mice, the severity of these symptoms was by far greater than that of the 
miRNA-155-/- mice following the AOM/DSS protocol.  These results imply that 
miRNA-155 may serve as an important therapeutic target in colorectal cancer; blocking 
miRNA-155 may reduce the severity of symptoms in colorectal cancer patients.   
Body composition was also examined as weight loss, including fat loss, has been 
associated with colorectal cancer.  Cancer cachexia is a wasting disorder in which 
patients have a significantly decreased appetite without actively trying to lose weight 1, 2, 
10
.  In fact, patients with cancer cachexia lose a significant amount of weight quickly even 
when an increased caloric intake is administered.  One of the determining factors of 
cachexia is the loss of lean fat mass while consuming a high calorie diet.  Although in the 
current experiment we did not observe a significant decrease in lean mass in the wild-
type AOM/DSS mice compared to the disease-free control group there was a trend 
towards a decrease.  Whereas the miRNA-155-/- had a very similar lean mass to the 
disease-free control mice.  There was however, a significant decrease in fat mass as well 
as body fat percentage observed in the wild-type mice that were not seen in the miRNA-
155-/- mice.  In addition, epididymal, mesenteric and kidney fat weight were all reduced 
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at sacrifice in the wild-type group and miRNA-155-/- offset this effect.  In general, the 
miRNA-155 knockout mice had a more similar body composition to the disease-free 
control group than the wild-type group of mice.  This suggests that targeting miRNA-155 
in colorectal cancer patients could possibly reduce the occurrence of cancer cachexia 
allowing patients a greater chance of maintaining a stable body composition.   
While we did not explore specific mechanisms of action that may be contributing 
to benefits of miRNA-155 deficiency in this model there are several possible 
explanations.  Firstly, miRNA-155 may be promoting angiogenesis 9.   For example, it 
has been reported that miRNA-155 can downregulate von Hippel-Lindau (VHL) tumor 
suppressor in breast cancer 9.  VHL acts through stimulating hypoxia-inducible factor 
(HIFα) family proteins to inhibit the stimulation of vascular endothelial growth factor 
(VEGF), an important promoter of angiogenesis 9.  Secondly, it has been shown to down-
regulate the tumor suppressor CDC73 in various cancer models 11.  For instance, 
expression of miRNA-155 in a squamous cell carcinoma cell line dramatically reduced 
CDC73 levels, enhanced cell viability, and decreased apoptosis.  Conversely, the delivery 
of a miRNA-155 antagonist (antagomir-155) to cells overexpressing miRNA-155 
resulted in increased CDC73 levels, decreased cell viability, increased apoptosis, and 
marked regression of xenografts in nude mice 11.  Thirdly, miRNA-155 has been reported 
to be a positive regulator of inflammatory processes 8, 19.  One study reported that both 
miRNA-155 overexpression and an inflammatory environment increased the frequency 
of mutations and down-regulated a kinase that blocks cell-cycle progression indicating 
that miRNA-155 may be a key player in the treatment of inflammation-related cancers 19.  
Similarly, a recent study reported that miRNA-155 expression is inversely correlated with 
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expression of suppressor of cytokine signaling (SOCS1), a negative regulator of 
inflammation, in breast cancer cell lines as well as in a subset of primary breast tumors 8.  
While our data shows promising effects for a benefit of miRNA-155 deficiency 
on colorectal cancer and associated symptoms there are several limitations of this study.  
Firstly, we did not investigate potential targets of miRNA-155 or mechanisms of action 
of miRNA-155 in this model; this study was limited to examination of tumor number and 
symptom severity.  Secondly, the mice developed relatively few tumors, which may have 
precluded observation of the true effects of miRNA-155 deficiency.  Therefore this study 
should be repeated with higher doses of AOM and/or DSS to enhance tumorigenesis.  
Further, pathways and mechanisms whereby miRNA-155 may have mediated its effects 
on colorectal cancer should be explored.  Lastly, anytime a global knockout mouse model 
is used there is always some speculation as to the clinical translation; having absolutely 
no presence of miRNA-155 may not fully show what the effects of possible therapeutics 
would provide in a human.   
In summary, our data indicates that miRNA-155 plays a significant role in 
tumorigenesis as well as the symptoms associated with colorectal cancer; mice deficient 
for miRNA-155 had a significant reduction in the number of tumors in the colon and this 
was associated with decreased sickness symptoms and prevention of loss of body weight 
and fat mass that accompany the disease.  Future research should be performed to 
confirm these findings along with the examination of the mechanisms of action of 
miRNA-155.  If these findings can be clinically translated miRNA-155 may lead to an 
effective clinical biomarker and/or therapeutic target in colorectal cancer. 
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TABLE 1. SYMPTOM SCORING 
Symptom Scoring 
 0 2 4 
Diarrhea  Well-formed pellet Pasty and semi-
formed stools that 
do not adhere to the 
anus  
Liquid stools that 
adhere anus  
Blood in stools  No blood  Positive hemoccult Gross bleeding 
Weight Loss 0-5% weight loss 11-15% weight loss  >20% weight loss 
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FIGURE 1. 
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FIGURE 3. 
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FIGURE 4. 
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FIGURE 5.  
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